$MMS

Maximus Cuts FY26 Adj. EPS Outlook; Stock Down 5% - Update

Maximus, Inc. (MMS) reported third-quarter results and cut its FY2026 adjusted EPS outlook to $7.90-$8.20 per share from $8.25-$8.55, citing a temporary contractual change on a major federal program. It kept FY2026 sales guidance at $5.20 billion-$5.35 billion, toward the lower end. Shares were down about 5% premarket to $59.86.

Original reporting
Published Aug 6, 2026, 11:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 12:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Maximus Cuts FY26 Adj. EPS Outlook; Stock Down 5% - Update — source image
Decision brief

The 30-second read

$MMSBearishMed
01

Why it matters

The guidance reduction is the key tradable input, likely prompting estimate revisions and multiple compression if investors view the modification as margin-negative or earnings-timing adverse.

02

Market read

A concrete FY26 EPS range cut with a stated contractual cause, alongside a pre-market ~5% decline, makes this a direct repricing event for MMS.

03

What to watch

The article does not quantify the magnitude or duration of the contractual modification, so the market may be over-discounting if the impact reverses in later quarters.

Relevance 8/10Novelty 7/10Timing: pre-market today guidance cut and stock down ~5%

Background

Maximus reported Q3 results and simultaneously revised full-year 2026 adjusted EPS guidance downward, citing a temporary contractual modification on a major federal program.

Company-level read

Ticker impact

$MMSBearishMedium confidence
Context

Maximus cut its FY2026 adjusted EPS outlook to $7.90-$8.20 from $8.25-$8.55 due to a temporary contractual modification on a major federal program.

Expected impact

Bearish bias for the next few sessions as traders reprice FY26 EPS and margin assumptions tied to the federal program modification.

Evidence & confidence

The article provides a concrete EPS range reduction and notes the cause is a contractual modification, which typically implies less favorable economics or timing versus prior expectations.

Market effects

Federal-services contractors may see read-across risk if contractual modifications affect earnings visibility or margins.

Limited, primarily impacts US small/mid-cap government services sentiment.

Low, largely company-specific guidance update.

Counterpoint

Sales guidance is maintained, suggesting the EPS cut may be temporary or accounting/timing related rather than a durable demand decline.

Key entities

  • Maximus, Inc.

    Lowered FY2026 adjusted EPS outlook to $7.90-$8.20 due to a temporary contractual modification on a major federal program, while keeping sales growth outlook.

Related articles

$MMSMed

Maximus Q3 Earnings Call Highlights

Maximus (NYSE:MMS) reported Q3 results and guidance on an earnings call. Revised guidance implies adjusted diluted EPS of $1.91 at the midpoint and ~13% adjusted EBITDA margin, with incentive eligibility paused through Dec. 31, 2026. U.S. Federal Services revenue was $721M, U.S. Services $418M, and Outside the U.S. $140M. Total debt was $1.65B, net leverage 2.0x, and it repurchased 750k shares for $50M.

$MMSMed

MAXIMUS, INC. (MMS): Results of Operations and Financial Condition

MAXIMUS, INC. (MMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mms-2026x06x30x8kxex991.htm EX-99.1 Document FOR IMMEDIATE RELEASE CONTACT: James Francis, VP - IR IR@maximus.com Date: August 6, 2026 Maximus Reports Fiscal Year 2026 Third Quarter Results Strong earnings performance reflects disciplined execution (Tysons, Va. - August

$NVOMedAI 8/10

Novo Nordisk A/S Q2 Earnings Call Highlights

Novo Nordisk reported Q2 adjusted sales of DKK 78.5 billion, with obesity care sales up 16% and GLP-1 diabetes up 2%. Adjusted gross margin fell to 78.2% from 82.7% due to lower prices, about DKK 3 billion one-time manufacturing-cost items, and FX. The company raised 2026 outlook to 0% to -6% adjusted sales and operating profit growth. ZEUS ziltivekimab trial missed its primary endpoint (HR 0.99).

$NYTMed

New York Times Q2 Earnings Call Highlights

The New York Times Company (NYSE:NYT) reported Q2 results on its earnings call. Digital-only subscribers rose 13.3% YoY and digital-only ARPU increased 3.1%. First-half free cash flow was about $266M and the company returned about $160M to shareholders. It guided Q3 digital-only subscription revenue up 12% to 15% and digital ad revenue up mid- to high-teens.

$OCMed

Owens Corning Q2 Earnings Call Highlights

Owens Corning (NYSE:OC) said Iran-related net cost impact is expected to be about $40 million in Q3, with roofing the most affected segment. The company reported Q2 liquidity of $1.8 billion and plans to repay $400 million of senior notes in Q3. Full-year capex is about $800 million. Roofing Q2 sales were ~$1.3 billion; insulation revenue rose 4% to $971 million.